HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
CNTA
Centessa Pharmaceuticals plc
Healthcare Biotechnology · United Kingdom · Reports in usd
Market Cap: $6.12B
Market Cap
$6.12B
Enterprise Val
$5.96B
P/E Ratio
-24.42
P/B Ratio
12.56
Trailing PEG (1Y)
-0.15
As Of
May 13, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$487.3M
Return on Equity-60.37%
Return on Assets-44.17%
Current Ratio9.53
Debt/Equity0.24
LT Debt/Equity0.24
Revenue Per Share0.00

Income Statement

Mar 31, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$59.9M
SG&A$19.9M
Operating Expenses$79.8M
Operating Income-$79.8M
Interest Expense$2.7M
Tax Expense$850.0K
Net Income-$79.2M
EPS (Basic)$-0.52
EPS (Diluted)$-0.52
EBIT-$75.7M
EBITDA-$75.4M
Consolidated Income-$79.2M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$62.4M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$348.7M
LT Investments$257.1M
Property, Plant & Equipment$10.5M
Intangibles$0.00
Non-Current Assets$293.1M
Total Assets$641.8M
Accounts Payable$10.7M
Current Debt$0.00
Current Liabilities$36.6M
LT Debt$117.8M
Non-Current Liabilities$117.8M
Total Liabilities$154.4M
Total Debt$117.8M
Retained Earnings-$1.27B
Shareholder Equity$487.3M
Shares Outstanding154,568,531

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$72.2M
Investing Cash Flow$42.7M
Financing Cash Flow$30.5M
CapEx$0.00
Free Cash Flow-$72.2M
Depreciation & Amort.$239.0K
Stock-Based Comp$10.6M
Acquisitions / Disposals$0.00
Investment Activity$42.7M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$34.1M
Dividends Paid$0.00
Net Change in Cash$1.1M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h